Verano Holdings Joins DEA Schedule III Registration Race

The Starting Gun Has Fired for Federal Cannabis Registration

On May 13, 2026, Verano Holdings Corp. became one of the latest major multistate operators to announce it had filed applications with the Drug Enforcement Administration to register its state-licensed medical cannabis operations under Schedule III. The move follows the DOJ's April 23 rescheduling order that shifted FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III, a category shared by drugs like ketamine and certain codeine formulations.

Verano's filing covers a sprawling footprint: 162 Zen Leaf and MÜV dispensaries, 14 production facilities, and more than 1.1 million square feet of cultivation capacity across 13 states. Founder and CEO George Archos called the submission a milestone on the company's path toward operating as a federally recognized business.

But Verano is far from alone in this sprint. Trulieve Cannabis, which operates more than 200 medical dispensaries, had already begun submitting its applications weeks earlier, aiming to be among the first MSOs processed through the DEA's expedited review pathway. The clock is ticking: operators that submit Form 225 within 60 days of the rule's publication — by June 27, 2026 — receive priority review status.

What DEA Registration Actually Requires

The registration process isn't merely a formality. The DEA's dispensary portal went live on April 29, and new application forms for cultivators, manufacturers, testing laboratories, and distributors are expected in the coming weeks. Each category carries its own annual fee structure: manufacturers pay $3,699, distributors $1,850, and dispensers $888 every three years.

Beyond fees, applicants must demonstrate compliance with DEA security requirements, maintain detailed record-keeping systems, and submit to inspections. For operators accustomed to navigating state-level regulatory frameworks, the federal layer introduces a new dimension of oversight that many compliance teams are encountering for the first time.

Firms that already submitted Form 225 applications will be contacted directly by the DEA for processing, eliminating the need to reapply. This detail matters for early movers who filed before the formal portal opened.

Why MSOs Are Racing the Clock

The June 27 priority window creates genuine urgency. Companies that miss the deadline can still register, but they lose expedited processing status — and in a market where timing can determine competitive advantage, falling behind on federal compliance could prove costly.

The benefits of registration extend beyond optics. Schedule III classification effectively neutralizes the impact of IRS Section 280E, which has prevented cannabis businesses from deducting ordinary operating expenses for years. For large MSOs carrying hundreds of millions in annual revenue, the tax savings alone could reshape balance sheets.

Registration also opens pathways to more conventional banking relationships, insurance products, and potentially even institutional investment. While major banks remain cautious pending explicit safe-harbor legislation, the shift from Schedule I to Schedule III removes one of the most significant legal barriers that kept traditional financial institutions at arm's length.

The Broader Registration Landscape

Oklahoma regulators have already issued warnings to medical marijuana businesses in the state, urging them to obtain DEA Schedule III registration without delay. The message reflects a growing consensus among state officials: federal registration is not optional for operators who want to remain competitive and compliant in the post-rescheduling landscape.

The DEA's approach has drawn both praise and criticism. Supporters argue the expedited pathway demonstrates federal agencies' willingness to accommodate an industry serving millions of patients. Critics counter that the dual-track system — medical cannabis under Schedule III while recreational remains Schedule I — creates operational headaches for operators whose facilities handle both markets.

What Comes Next: The June 29 Hearing

Adding another layer of complexity, the DEA will hold administrative hearings beginning June 29 to evaluate whether all marijuana, including adult-use products, should join medical cannabis under Schedule III. The outcome of those hearings could fundamentally alter the regulatory landscape for every cannabis business in the country.

For now, MSOs like Verano and Trulieve are focused on what they can control: filing paperwork, paying fees, and preparing their operations for a level of federal scrutiny that would have been unimaginable just a few years ago.

The Bottom Line for Operators

The DEA registration race is a defining moment for the cannabis industry's maturation. Companies that move quickly and invest in compliance infrastructure are positioning themselves for a future where federal legitimacy is table stakes rather than a competitive edge. Those that delay risk finding themselves on the wrong side of a regulatory divide that grows wider with each passing week.

The question is no longer whether cannabis will operate within a federal regulatory framework, but how quickly individual companies can adapt to one that is taking shape in real time.